Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002097 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.
A Phase 1 study, sponsored by Argus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00002097: Completed Phase 1 study, sponsored by Argus Pharmaceuticals.
NCT00002097 is a Phase 1 study that has completed, run by Argus Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002097, a Phase 1 study, has completed, sponsored by Argus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
Interventions
- DRUG Nystatin
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002097
The ClinicalTrials.gov registry entry for NCT00002097 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Argus Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nystatin is the first listed.
NCT00002097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002097 about?
NCT00002097 is a clinical study titled "A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.". To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and clinical pharmacology of intravenous nystatin.
What is the current status of trial NCT00002097?
This trial is currently completed. It is a Phase 1 study.
What interventions are being tested in trial NCT00002097?
The interventions under investigation include: Nystatin (DRUG).
Who is sponsoring clinical trial NCT00002097?
This trial is sponsored by Argus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.